Actinium Pharmaceuticals
Dirigeants
Voir l'organigramme avec ses 20 principaux dirigeants
Biographies les plus recherchées chez Actinium Pharmaceuticals
- Sandesh Seth, Chairman of the Board and Chief Executive Officer
- David Nicholson, Lead Independent Director
- Richard Steinhart, Director
Changements de dirigeants chez Actinium Pharmaceuticals
- Lynn Bodarky, a rejoint l'entreprise comme Chief Business Officer (publié le 3 novembre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Actinium Pharmaceuticals.
Pharmacie
Actinium Pharmaceuticals a 1 860 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- MedMen has filed for bankruptcy protection (publié le 28 avril 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Actinium Pharmaceuticals
- Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting :: Actinium Pharmaceu
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annua
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMT
- Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIB
- Press Releases :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition :: Actinium Pharmaceuticals, Inc. (ATNM)
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Actinium Pharmaceuticals
- Actinium Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Actinium Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
